WALTHAM, Mass., March 30, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that it has entered into a research collaboration agreement with Boston Scientific Corporation, a leading medical device manufacturer, to study the role of galectin-3 as an aid in patient screening for cardiac-resynchronization therapy (CRT) using patient data from the MADIT-CRT study. The collaboration is designed to focus on better understanding the important MADIT-CRT patient population and whether galectin-3 can help identify patients who would derive the most benefit from CRT. This collaboration also involves using BG Medicine's biomarker discovery capabilities to identify other biomarkers that correlate to CRT treatment response.
The U.S. Food and Drug Administration recently cleared the BG Medicine galectin-3 assay as an aid in assessing the prognosis of patients with chronic heart failure. Elevated galectin-3 levels are associated with an inherently progressive form of heart failure that is associated with an increased risk of hospitalization or death.
"Guidelines for CRT candidate selection are based on measures of current cardiac status, not on the basis of anticipated disease course," noted Pieter Muntendam, M.D., President and CEO of BG Medicine. "Elevated galectin-3 is associated with poor outcomes, and this collaboration aims to investigate the role galectin-3 can play in identifying those who stand to gain most by early use of CRTs."
MADIT-CRT is the world's largest randomized CRT-D study of New York Heart Association (NYHA) Class I and II patients, with more than 1,800 patients enrolled at 110 centers worldwide. Results of the MADIT-CRT trial were published in the October 2009 issue of the New England Journal of Medicine.
About Heart Failure
Heart failure is caused by a combination of factors involving structural changes that reduce blood flow and damage or overwork the heart muscle, so that it cannot circulate blood efficiently to meet the needs of other body organs. Heart failure may lead to serious medical complications and is a leading cause of death. According to the American Heart Association, heart failure affects an estimated 5.7 million Americans with 670,000 new diagnoses each year. The estimated direct and indirect cost of this condition in the U.S. is $39.2 billion annually.
About Cardiac-Resynchronization Therapy
Cardiac-Resynchronization Therapy (CRT), also known as bi-ventricular pacing, is a treatment for heart failure that uses an implantable device to improve the pumping efficiency of the heart. CRT has been shown to significantly reduce risk of death and hospitalization in certain groups of patients.
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.
The BG Medicine Inc. logo is available at
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit .
Forward Looking Statements
This press release may contain forward-looking statements which are made pursuant to the safe harbor provisions of Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "is designed to", "expects", "confident", "aims", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or the negative thereof or variations thereof or similar expressions intended to identify forward-looking statements. These statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Disclosures regarding the risks and uncertainties faced by the Company are contained in our public filings with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K under the heading "Risk Factors", which is available on the Company's investor relations website at and on the SEC's website at .
CONTACT: Michael W. Rogers EVP & Chief Financial Officer (781) 890-1199
